Ingmar Bruns

Chief Tech/Sci/R&D Officer at ZENTALIS PHARMACEUTICALS, INC.

Net worth: 121 337 $ as of 30/06/2026

51 year

Health Technology

Consumer Services

Profile

Ingmar Bruns is currently the Chief Medical Officer at Zentalis Pharmaceuticals, Inc. He previously held the position of Chief Medical Officer at Trillium Therapeutics, Inc. from 2020 to 2021.
He also worked as the Senior Vice President-Clinical Development at Pieris Pharmaceuticals, Inc. Dr. Bruns obtained a doctorate degree from Universität zu Lübeck.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
ZENTALIS PHARMACEUTICALS, INC. 0.04%	20/04/2026	25,018 ( 0.04% )	121 337 $	30/06/2026

Ingmar Bruns active positions

Companies	Position	Start
ZENTALIS PHARMACEUTICALS, INC.	Chief Tech/Sci/R&D Officer	13/11/2024

All active positions of Ingmar Bruns

Former positions of Ingmar Bruns

Companies	Position	End
TRILLIUM THERAPEUTICS	Chief Tech/Sci/R&D Officer	17/11/2021
PIERIS PHARMACEUTICALS	Corporate Officer/Principal	-

See the detail of Ingmar Bruns's experience

Training of Ingmar Bruns

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Ingmar Bruns's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
Trillium Therapeutics, Inc. Trillium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures medicines & therapies for cancer	Health Technology
Universität zu Lübeck Universität zu Lübeck Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Pieris Pharmaceuticals, Inc. Pieris Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and markets an anticalin-brand protein technology	Health Technology
Zentalis Pharmaceuticals, Inc. Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways	Health Technology